All In Biotech

Drug Trial Radar · NCT02453282

Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)

A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 in Combination With Tremelimumab Therapy or MEDI4736 Monotherapy Versus Standard of Care Platinum-Based Chemotherapy in First Line Treatment of Patients With Advanced or Metastatic Non Small-Cell Lung Cancer (NSCLC)(MYSTIC).

Last checked: Nov 20, 2026Latest source record: Aug 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,118 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

1,118

Actual

Start

Jul 21, 2015

Primary completion

Oct 4, 2018

Study completion Dec 31, 2026

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
May 25, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 130 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, open-label, multi-center, global, Phase III study to determine the efficacy and safety of MEDI4736 + tremelimumab combination therapy and MEDI4736 monotherapy versus platinum-based SoC chemotherapy in the first-line treatment of patients with epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) wild-type locally advanced or metastatic NSCLC

Conditions

  • Non-Small-Cell Lung Carcinoma NSCLC

Interventions

  • MEDI4736 (Durvalumab)Biological

  • MEDI4736 (Durvalumab)+TremelimumabBiological

  • Paclitaxel + CarboplatinDrug

    Chemotherapy Agents

  • Gemcitabine + CisplatinDrug

    Chemotherapy Agents

  • Gemcitabine + CarboplatinDrug

    Chemotherapy Agents

  • Pemetrexed + CisplatinDrug

    Chemotherapy Agents

  • Pemetrexed + CarboplatinDrug

    Chemotherapy Agents

  • TremelimumabBiological

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (OS); PD-L1 (TC >=25%) Analysis Set Population, Durvalumab Monotherapy Vs SoC Chemotherapy and Durvalumab + Tremelimumab Vs SoC ChemotherapyTime frame: From baseline (Day 1, Week 0) until death due to any cause, assessed up to the data cut-off date (a maximum of approximately 3 years).
  2. Progression-Free Survival (PFS); PD-L1 (TC >=25%) Analysis Set Population, Durvalumab + Tremelimumab Vs SoC ChemotherapyTime frame: Tumour scans performed at baseline then every 6 weeks up to 48 weeks relative to the date of randomization, then every 8 weeks thereafter until confirmed disease progression. Assessed up to the data cut-off date (a maximum of approximately 3 years).

Locations

196 sites in 17 countries. Site status is shown where the registry gives one.

  • Research Site

    Scottsdale, Arizona

  • Research Site

    Tucson, Arizona

  • Research Site

    Yuma, Arizona

  • Research Site

    Bakersfield, California

  • Research Site

    Fullerton, California

  • Research Site

    La Jolla, California

  • Research Site

    Los Angeles, California

  • Research Site

    Los Angeles, California

  • Research Site

    Redondo Beach, California

  • Research Site

    Sacramento, California

  • Research Site

    San Luis Obispo, California

  • Research Site

    Santa Maria, California

  • Research Site

    West Hollywood, California

  • Research Site

    New Haven, Connecticut

  • Research Site

    Jacksonville, Florida

  • Research Site

    Pembroke Pines, Florida

  • Research Site

    Tampa, Florida

  • Research Site

    Athens, Georgia

  • Research Site

    Honolulu, Hawaii

  • Research Site

    Baltimore, Maryland

  • Research Site

    Minneapolis, Minnesota

  • Research Site

    St Louis, Missouri

  • Research Site

    Omaha, Nebraska

  • Research Site

    Summit, New Jersey

  • Research Site

    Mineola, New York

  • Research Site

    New York, New York

  • Research Site

    New York, New York

  • Research Site

    New York, New York

  • Research Site

    Charlotte, North Carolina

  • Research Site

    Cleveland, Ohio

  • Research Site

    North Charleston, South Carolina

  • Research Site

    Nashville, Tennessee

  • Research Site

    Nashville, Tennessee

  • Research Site

    Richmond, Virginia

  • Research Site

    Madison, Wisconsin

  • Research Site

    Box Hill, Australia

  • Research Site

    Gosford, Australia

  • Research Site

    Kogarah, Australia

  • Research Site

    Melbourne, Australia

  • Research Site

    Port Macquarie, Australia

Showing 40 of 196 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.